Shiota Naotaka, Rysä Jaana, Kovanen Petri T, Ruskoaho Heikki, Kokkonen Jorma O, Lindstedt Ken A
Wihuri Research Institute, Helsinki, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland.
J Hypertens. 2003 Oct;21(10):1935-44. doi: 10.1097/00004872-200310000-00022.
Cardiac mast cells participate in myocardial dysfunction, but the mechanisms are presently unknown.
By examining spontaneously hypertensive rats (SHRs) during their entire lifespan, we attempted to define the role of mast cells in the induction of cardiac hypertrophy and transition to heart failure.
By contrast to normotensive littermates, hearts of newborn SHRs already contained mast cells. In the prehypertensive (2-week-old) SHRs, the increased expression of c-kit and soluble stem cell factor correlated with an increased number of cardiac mast cells. The mast cells contained tumour necrosis factor-alpha which, together with nuclear factor kappa-B (NF-kappaB) and interleukin (IL)-6, was significantly induced in the prehypertensive SHRs. Stimulation of cardiac mast cells with compound 48/80 in an ex-vivo Langendorff heart perfusion system resulted in increased expression of nuclear factor Kappa-B (NF-kappaB) (four-fold) and IL-6 (nine-fold) mRNA in the left ventricles of adult rat hearts. In the presence of an inhibitor of mast cell degranulation, disodium cromoglycate, the induced expression of NF-kappaB and IL-6 was inhibited. In the late hypertensive stage, the hearts of SHRs with advanced cardiac hypertrophy (12-month-old) and heart failure (20-month-old) had significantly increased levels of transforming growth factor (TGF)-beta1 and basic fibroblast growth factor (bFGF), and displayed increased myocardial fibrosis. Activated mast cells were a major source of TGF-beta1 and bFGF, and localized to areas of myocardial fibrosis.
By synthesizing and secreting prohypertrophic cytokines and profibrotic growth factors, cardiac mast cells participate in the induction of cardiac hypertrophy and cardiac fibrosis, which are the key steps in the transition to heart failure.
心脏肥大细胞参与心肌功能障碍,但目前其机制尚不清楚。
通过在整个寿命期内检查自发性高血压大鼠(SHR),我们试图确定肥大细胞在诱导心脏肥大和向心力衰竭转变中的作用。
与正常血压的同窝仔鼠相比,新生SHR的心脏中已含有肥大细胞。在高血压前期(2周龄)的SHR中,c-kit和可溶性干细胞因子的表达增加与心脏肥大细胞数量的增加相关。肥大细胞含有肿瘤坏死因子-α,其与核因子κB(NF-κB)和白细胞介素(IL)-6一起在高血压前期的SHR中显著诱导表达。在离体Langendorff心脏灌注系统中用化合物48/80刺激心脏肥大细胞,导致成年大鼠心脏左心室中核因子κB(NF-κB)(四倍)和IL-6(九倍)mRNA的表达增加。在存在肥大细胞脱颗粒抑制剂色甘酸钠的情况下,NF-κB和IL-6的诱导表达受到抑制。在高血压晚期,患有晚期心脏肥大(12月龄)和心力衰竭(20月龄)的SHR心脏中转化生长因子(TGF)-β1和碱性成纤维细胞生长因子(bFGF)水平显著升高,并显示心肌纤维化增加。活化的肥大细胞是TGF-β1和bFGF的主要来源,并定位于心肌纤维化区域。
心脏肥大细胞通过合成和分泌促肥大细胞因子和促纤维化生长因子,参与心脏肥大和心脏纤维化的诱导,而这是向心力衰竭转变的关键步骤。